CORRECTING and REPLACING: Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting
April 25 2017 - 4:40PM
Business Wire
Regulatory News:
This replaces the announcement made at 22:30 CET April 25, 2017
due to the following corrections: Under "Oral presentation," the
second line should read: Philippe Duchateau, PhD. Chief Scientific
Officer, Cellectis.
Cellectis to Present at the American Society
of Gene & Cell Therapy Annual Meeting
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq:
CLLS), a biopharmaceutical company focused on developing
immunotherapies based on gene edited CAR T-cells, today announced
that data on its gene-edited allogeneic off-the-shelf CAR T-cell
immunotherapies (UCART) will be presented at the ASGCT 20th Annual
Meeting. The meeting will be held from May 10th to 13th, 2017 in
Washington, D.C., USA.
Oral presentation:
Development of Gene Edited Allogeneic CAR T-Cell
TherapyPhilippe Duchateau, PhD. Chief Scientific Officer,
Cellectis
Session: 300 - Clinical Advancement of Gene Editing-Moving New
Science to the Clinic - Organized by the Clinical Trials and
Regulatory Affairs Committee
Friday, May 12, 2017 from 8:35 AM to 9:10 AM ESTLincoln 2, 3,
4
Poster presentations:
176 - Genome-Wide Analysis of TALEN® Activity in Primary
CellsBrian Busser, Sonal Temburni, Aymeric Duclert, Philippe
Duchateau and Laurent Poirot
Session: Gene Targeting and Gene Correction IWednesday May 10,
2017 at 5:30 PM ESTExhibit Hall A & B South
114 - UCART22: An Allogeneic Adoptive Immunotherapy for
Leukemia Targeting CD22 with CAR T-cellsAnne-Sophie Gautron,
Cécile Schiffer-Mannioui, Alan Marechal, Severine Thomas, Agnes
Gouble, Laurent Poirot, Julianne Smith
Session: Cancer-Immunotherapy, Cancer Vaccines IWednesday May
10, 2017 from 5:30 PM to 7:30pm ESTExhibit Hall A & B South
372 - Manufacturing of Gene-Modified Mouse CAR
T-CellsLaurent Poirot, Brian Busser, Sonal Temburni,
Philippe Duchateau
Session: Gene Targeting and Gene Correction IIThursday May 11,
2017 from 5:15 PM to 7:15 PM ESTExhibit Hall A & B South
About Cellectis
Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene-edited CAR T-cells (UCART). The
company’s mission is to develop a new generation of cancer
therapies based on engineered T-cells. Cellectis capitalizes on its
17 years of expertise in genome engineering - based on its flagship
TALEN® products and meganucleases as well as its pioneering
electroporation PulseAgile technology - to create a new generation
of immunotherapies. CAR technologies are designed to target surface
antigens expressed on cells. Using its life-science-focused,
pioneering genome-engineering technologies, Cellectis’ goal is to
create innovative products in multiple fields and with various
target markets.
Cellectis is listed on the Nasdaq market (ticker: CLLS) and on
the NYSE Alternext market (ticker: ALCLS). To find out more about
us, visit our website: www.cellectis.com
Talking about gene editing? We do it. TALEN® is a registered
trademark owned by the Cellectis Group
Disclaimer
This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an
offer to buy or subscribe, for shares in Cellectis in any country.
This press release contains forward-looking statements that relate
to the Company’s objectives based on the current expectations and
assumptions of the Company’s management only and involve risk and
uncertainties that could cause the Company to fail to achieve the
objectives expressed by the forward-looking statements above.
# # #
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170425006952/en/
For further information, please contact:Media
contacts:CellectisJennifer Moore, 917-580-1088VP of
Communicationsmedia@cellectis.comorKCSA Strategic
CommunicationsCaitlin Kasunich,
212-896-1241ckasunich@kcsa.comorIR contact:Simon Harnest,
646-385-9008VP of Corporate Strategy and
Financesimon.harnest@cellectis.com
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Apr 2024 to May 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From May 2023 to May 2024